Inventor
Mona Patel
Inventor
Belle Mead, NJ, US
Overview
Patents· 20 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations38%
C07DHeterocyclic compounds36%
C07HSugars15%
A61KPreparations for medical, dental or toiletry purposes5%
C07CAcyclic or carbocyclic compounds3%
F01MLubricating of machines or engines in general3%
PatentTitleYear
7,928,246'Dihydroisoindolones as allosteric modulators of glucokinase'20117,825,110'Substituted spiroheterocycles'20107,825,111'Substituted spiroheterocycles'20107,820,630'Substituted indole-O-glucosides'20107,816,331'Substituted indazole-O-glucosides'20107,687,494'Substituted spirobenzazepines'20107,531,671'Dihydroisoindolones as allosteric modulators of glucokinase'20097,511,022'Substituted indole-O-glucosides'20097,511,021'Substituted indazole-O-glucosides'20097,129,220'Substituted indole-O-glucosides'20067,084,124'Substituted indazole-O-glucosides'20066,969,721'Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors'20056,596,729'Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors'20036,593,337'Tricyclic compounds useful as HIV reverse transcriptase inhibitors'20036,492,515'4,4-disubstituted-1, 4-dihydro-2H-3, 1-benzoxazin-2-ones useful as HIV reverse transcriptase inhibitors and intermediates and processes for making the same'20026,303,780'4,4-disubstituted-1,4-dihydro-2h-3,1-benzoxazin-2-ones useful as HIV reverse transcriptase inhibitors and intermediates and processes for making the same'20016,265,406'Substituted quinolin-2 (1H) -ones useful as HIV reverse transcriptase inhibitors'20016,225,317'Crystalline (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-3,4-dihydro-2(1H)-quin azolinone'20016,090,821'Substituted quinolin-2 (1H)-ones useful as HIV reverse transcriptase inhibitors'20005,874,430'4,4-disubstitued-1,4-dihydro-2H-3,1-benzoxazin-2-ones useful as HIV reverse transcriptase inhibitors and intermediates and processes for making the same'1999Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
1999–2001Patents assigned to DU PONT PHARM CO (4)· patent assignee history
1999–2002Based in Wilmington, DE, US· patent location history
2000Patents assigned to DU PONT (1)· patent assignee history
2002–2003Patents assigned to BRISTOL MYERS SQUIBB PHARMA CO (2)· patent assignee history
2003–2011Based in Belle Mead, NJ, US· patent location history
2003Based in Bridgewater, NJ, US· patent location history
2005Patents assigned to BRISTOL MYERS SQUIBB PHARMA (1)· patent assignee history
2006–2011Patents assigned to JANSSEN PHARMACEUTICA NV (11)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| JANSSEN PHARMACEUTICA NV | 11 | 2006–2011 |
| DU PONT PHARM CO | 4 | 1999–2001 |
| BRISTOL MYERS SQUIBB PHARMA CO | 2 | 2002–2003 |
| BRISTOL MYERS SQUIBB PHARMA | 1 | 2005 |
| DU PONT | 1 | 2000 |
Locations
| Location | Patents | Span |
|---|---|---|
| Belle Mead, New Jersey, US | 13 | 2003–2011 |
| Wilmington, Delaware, US | 6 | 1999–2002 |
| Bridgewater, New Jersey, US | 1 | 2003 |